Riskpilot← Back to searchSign inGet full accessPharmacyl AB
ABBankruptOrg 5591601629Research and experimental development on natural sciences and engineering · NACE 7210Est. 20180 employees
Revenue 2024
SEK 365K
EBITDA margin
-26.7%
+23% vs 2023
Equity ratio
-2.7%
Financial strength
Net profit 2024
SEK -167K
+22% vs 2023
| Revenue | SEK 365K | — |
| EBITDA | SEK -97K | +23% |
| Net profit | SEK -167K | +22% |
| Total assets | SEK 2,4M | +20% |
| Equity | SEK -65K | -164% |
| Employees | 0 | — |
Legal name
Pharmacyl AB
Org number
5591601629
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25 maj 2018
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Forskning och utveckling av läkemedel.
Address
Email
jan.alenfall@callipa.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 70 | 0 | 0 | — | 0 | 0 | 365 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | −1 | −18 | −78 | 0 | −90 | −126 | −97 |
| Depreciation & amort. | −10 | −10 | −10 | — | −10 | −10 | −10 |
| EBIT | −11 | −28 | −88 | 0 | −100 | −136 | −107 |
| Net financials | — | −5 | −13 | — | −47 | −79 | −60 |
| Profit before tax | −11 | −33 | −101 | 0 | −147 | −214 | −167 |
| Tax | −0 | −0 | −0 | — | −0 | −0 | — |
| Net profit | −11 | −33 | −101 | — | −147 | −214 | −167 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 100 | 562 | 1 173 | — | 2 037 | 1 980 | 2 384 |
| Equity | 89 | 56 | −44 | — | 157 | 102 | −65 |
| Long-term debt | 0 | 500 | 1 150 | — | 1 778 | 1 684 | 2 051 |
| Short-term debt | 11 | 6 | 68 | — | 103 | 194 | 398 |
| Total debt | 11 | 506 | 1 218 | — | 1 881 | 1 878 | 2 449 |
EBITDA margin
-26.7%
This company
15.8%
Market median
-269% vs market
20182024
Equity ratio
-2.7%
This company
38.2%
Market median
-107% vs market
20182024
Return on equity
-16700200.0%
This company
18.4%
Market median
-90762057% vs market
20182024
Net profit margin
-45.8%
This company
8.1%
Market median
-665% vs market
20182024
Asset turnover
0.15×
This company
1.12×
Market median
-87% vs market
20182024
Debt / equity
37.75×
This company
0.62×
Market median
-5989% vs market
20182024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-05-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AK Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Chairman | 2025 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmacyl AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Karl Konrad Björk | Chief Executive Officer | 0 companies |
| Gunnar Eric Hedlund | Board of Directors | 0 companies |
| Gun Ester Birgitta Sanderheim | Deputy Board Member | 0 companies |
| Carl Peter Valentin Sjöbeck | Board of Directors | 0 companies |
| Jan Erik Alenfall | Board of Directors | 0 companies |
| Derek Gregory Batcheller | Board of Directors | 0 companies |
| Derek Gregory Batcheller | Board of Directors | 0 companies |
| Mats Joel Wiktor | Deputy Board Member | 0 companies |
| Per Anders Harald Henriksson | Chairman | 0 companies |